New Chinese vaccine easier to store, but not as effective as similar efforts
Sinopharm unit set to apply for authorisation
30 December 2020 - 10:49
Beijing — State-backed vaccine developer China National Biotec Group (CNBG) said one of its shots is effective in preventing Covid-19 in 79.3% of people, allowing it to apply for authorisation to market the inoculation for use in the general population.
The interim data shows the vaccine, which is already authorised for emergency use in China, is safe and people who took the shots in the trial all generated high levels of antibodies, according to a statement posted on the website of Beijing Biological Products Institute, a subsidiary of CNBG’s parent Sinopharm...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.